Relmada Therapeutics, Inc. reported a net loss of approximately $57.4 million for the fiscal year ending December 31, 2025, a decrease from a net loss of about $80 million in 2024. The company's accumulated deficit now stands at approximately $698.3 million. Total revenue remains nonexistent as Relmada continues to focus on the development of its clinical-stage product candidates, with no commercial products currently available. The decrease in net loss is attributed to reduced research and development expenses, which fell to approximately $26.9 million from $46.2 million in the previous year, primarily due to decreased consultant costs and stock-based compensation.
In terms of strategic developments, Relmada has undergone significant changes in its product pipeline. The company terminated its development programs for esmethadone and REL-P11 in 2025, redirecting its focus towards two new candidates: NDV-01 and sepranolone. NDV-01, a novel formulation for treating non-muscle invasive bladder cancer, is currently in Phase 2 trials, while sepranolone, a neurosteroid, is being developed for conditions such as Prader-Willi syndrome and Tourette syndrome. The acquisition of sepranolone from Asarina Pharma and the in-licensing of NDV-01 from Trigone Pharma were key milestones in this strategic pivot.
Operationally, Relmada's employee count stood at 17 as of December 31, 2025, reflecting a lean organizational structure as the company navigates its clinical development efforts. The company has also reported a significant increase in compensation expenses due to hiring additional research and development staff. The anticipated milestones for 2026 include the initiation of Phase 3 trials for NDV-01 and a Phase 2b study for sepranolone, with both expected to commence mid-year.
Looking ahead, Relmada's management believes that the existing cash and cash equivalents, along with recent financing activities, will support operations for at least the next 12 months. The company raised approximately $94 million from a public offering in late 2025 and has entered into a PIPE agreement for an additional $160 million. However, the company acknowledges the inherent risks associated with drug development, including the potential for delays in clinical trials and regulatory approvals, which could impact future financial performance and operational viability.
About RELMADA THERAPEUTICS, INC.
Relmada Therapeutics is a clinical-stage biotechnology company focused on developing novel drugs for neurological, psychiatric, and cancer-related conditions. Its pipeline includes candidates targeting depression, Tourette Syndrome, bladder cancer, and neurosteroid-related disorders. The company leverages extensive intellectual property, strategic licensing, and acquisitions to address high unmet medical needs, aiming for long-term growth through innovative, differentiated therapies in large markets.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.